Regulatory Story
Go to market news section View chart   Print
Company Smith & Nephew Plc
TIDM SN.
Headline

Directorate Change

Released 10:30 21-Feb-2013
Number 3860Y10

RNS Number : 3860Y
Smith & Nephew Plc
21 February 2013
 



 

 

 

Michael A. Friedman MD Appointed Non-Executive Director            

 

21 February 2013

 

 

Smith & Nephew plc (LSE: SN, NYSE: SNN), the global medical technology business, today announces the appointment of Michael A. Friedman MD as Non-Executive Director.  He will join the Board on 11 April 2013 and immediately offer himself for re-election at the Company's Annual General Meeting.

 

Michael has, for the past 10 years, been Chief Executive Officer of City of Hope, the prestigious cancer research and treatment institution in California.  He also serves as Director of the institution's comprehensive cancer centre and holds the Irell & Manella Cancer Center Director's Distinguished Chair.  He was formerly senior vice president of research and development, medical and public policy for Pharmacia Corporation and has served as Deputy Commissioner and Acting Commissioner at the US Food and Drug Administration.  He is an experienced Board director currently serving as Independent Director of Celgene Corporation and MannKind Corporation and having previously served as Independent Director of RiteAid Corporation.

 

Sir John Buchanan, Chairman of Smith & Nephew, commented:

 

"We are delighted that Michael Friedman has agreed to join the Board of Smith & Nephew.  He brings exceptional clinical and commercial experience of the US healthcare environment, a wealth of understanding of the US regulatory system and more than ten years' Board experience.  These skills will help Smith & Nephew meet the challenges and opportunities that lie ahead."

 

Michael Friedman MD commented:

 

"I am very much looking forward to joining the Board of Smith & Nephew, a company I have long admired.  Its programme to reshape to take advantage of the changing healthcare environment in the Established Markets, and its growing strength in the Emerging Markets, place it at the vanguard of the medical device industry.  I am delighted to be given the opportunity of working with Sir John, Olivier and the team to help deliver their strategy in the US and beyond."

No disclosure obligations arise under paragraphs (1) to (6) of LR 9.6.13 R of the UK Listing Authority's Listing Rules in respect of this appointment.

Enquiries

 

Investors

Phil Cowdy                                                                Tel:    +44 (0) 20 7401 7646

Smith & Nephew

 

Media

Charles Reynolds                                                     Tel:    +44 (0) 20 7401 7646

Smith & Nephew

 

Justine McIlroy / Andrew Mitchell                              Tel:    +44 (0) 20 7404 5959

Brunswick - London

                                                                                                            

 

About Smith & Nephew

Smith & Nephew is a global medical technology business dedicated to helping improve people's lives. With leadership positions in Orthopaedic Reconstruction, Advanced Wound Management, Sports Medicine and Trauma and Extremities, Smith & Nephew has almost 10,500 employees and a presence in more than 90 countries. Annual sales in 2012 were more than $4.1 billion. Smith & Nephew is a member of the FTSE100 (LSE: SN, NYSE: SNN).

 

Forward-looking Statements

This document may contain forward-looking statements that may or may not prove accurate. For example, statements regarding expected revenue growth and trading margins, market trends and our product pipeline are forward-looking statements. Phrases such as "aim", "plan", "intend", "anticipate", "well-placed", "believe", "estimate", "expect", "target", "consider" and similar expressions are generally intended to identify forward-looking statements. Forward-looking statements involve known and unknown risks, uncertainties and other important factors that could cause actual results to differ materially from what is expressed or implied by the statements. For Smith & Nephew, these factors include: economic and financial conditions in the markets we serve, especially those affecting health care providers, payors and customers; price levels for established and innovative medical devices; developments in medical technology; regulatory approvals, reimbursement decisions or other government actions; product defects or recalls; litigation relating to patent or other claims; legal compliance risks and related investigative, remedial or enforcement actions; strategic actions, including acquisitions and dispositions, our success in integrating acquired businesses, and disruption that may result from changes we make in our business plans or organisation to adapt to market developments; and numerous other matters that affect us or our markets, including those of a political, economic, business or competitive nature. Please refer to the documents that Smith & Nephew has filed with the U.S. Securities and Exchange Commission under the U.S. Securities Exchange Act of 1934, as amended, including Smith & Nephew's most recent annual report on Form 20-F, for a discussion of certain of these factors.

 

Any forward-looking statement is based on information available to Smith & Nephew as of the date of the statement. All written or oral forward-looking statements attributable to Smith & Nephew are qualified by this caution. Smith & Nephew does not undertake any obligation to update or revise any forward-looking statement to reflect any change in circumstances or in Smith & Nephew's expectations.

 

 

 

 


This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
BOAGCGDDGSDBGXB
Close


London Stock Exchange plc is not responsible for and does not check content on this Website. Website users are responsible for checking content. Any news item (including any prospectus) which is addressed solely to the persons and countries specified therein should not be relied upon other than by such persons and/or outside the specified countries. Terms and conditions, including restrictions on use and distribution apply.

 


Directorate Change - RNS